02017nas a2200421   4500000000100000008004100001260000900042653001000051653002500061653001500086653002400101653002600125653001700151653001700168653001100185653002200196653001600218653001100234653002300245653002500268653001100293653000900304653001800313653002500331653003100356653003000387653002800417653002200445100002100467700001300488700001900501700002400520245010600544300001000650490000700660520091400667022001401581       2003                            d  c200310aAdult10aAnalysis of Variance10aAntibodies10aAntigens, Bacterial10aAntitubercular Agents10aCardiolipins10aCerebrosides10aFemale10aFollow-Up Studies10aGlycolipids10aHumans10aLeprostatic Agents10aLeprosy, lepromatous10aLipids10aMale10aMycobacterium10aMycobacterium leprae10aMycobacterium tuberculosis10aStatistics, Nonparametric10aTuberculosis, Pulmonary10aVirulence Factors1 aRojas-Espinosa O1 aArenas R1 aArce-Parades P1 aMiranda-Contreras G00aAntibodies to diverse lipids in the serum of patients with clinically cured leprosy and tuberculosis.  a112-60 v123 a<p>In this study we looked for the presence of antibodies to cardiolipin, cerebrosides, and whole lipids extracted from M. leprae, M. tuberculosis and M. habana, in the serum of patients with clinically cured lepromatous leprosy (sixteen) or tuberculosis (sixteen), 8 to 12 months after arresting the corresponding multi-drug therapy (MDT). Compared to healthy controls (sixteen), both leprosy and tuberculosis ex-patients had still significant levels of antibodies to the three mycobacterial lipids but no detectable levels of antibodies to cardiolipin or cerebroside lipids. Although leprosy and tuberculosis sera recognized the homologous mycobacterial lipids in a preferential fashion, all of them, on the average, reacted more strongly with the lipids of M. habana. This observation backs up, in a certain way, the proposition of using M. habana as a prospective vaccine for leprosy and tuberculosis.</p>  a0001-5938